BioTech

Readout Newsletter: Amylyx, Parkinson’s, Moderna updates

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…

Read More »

Roivant drug for autoimmune conditions hits mark in eye disease

A drug being developed by a Roivant subsidiary for a range of autoimmune conditions succeeded in a mid-stage trial in…

Read More »

Amylyx to pull ALS drug from market, cut 70% of staff

Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga…

Read More »

Gritstone Bio says personalized cancer vaccine falls short in key trial

Gritstone Bio said Monday afternoon that its personalized cancer vaccine didn’t induce more responses than standard of care in a…

Read More »

Innomics, Gritstone, Otsuka, and more

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…

Read More »

Genmab to buy ProfoundBio, picking up targeted chemotherapies

LONDON — The Danish firm Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion in cash, the latest in…

Read More »

As AI proliferates, biopharma companies seek to harness it in clinical trials

For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images. That was until…

Read More »

For national security, the U.S. must maintain its biotech dominance

For more than a century, the United States has been the undisputed leader in medical and biotechnology innovation. It saved…

Read More »

Investors funnel $275 million into Paragon Therapeutics-spinout

Investors have funneled $275 million into a revamped biotech developing new psoriasis and psoriatic arthritis treatments that could be given…

Read More »

Roivant, Acorda, Merz, and Freenome

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…

Read More »